Cargando…

Frailty Markers and Treatment Decisions in Patients Seen in Oncogeriatric Clinics: Results from the ASRO Pilot Study

BACKGROUND: Comprehensive Geriatric Assessment (CGA) is the gold standard to help oncologists select the best cancer treatment for their older patients. Some authors have suggested that the concept of frailty could be a more useful approach in this population. We investigated whether frailty markers...

Descripción completa

Detalles Bibliográficos
Autores principales: Farcet, Anaïs, de Decker, Laure, Pauly, Vanessa, Rousseau, Frédérique, Bergman, Howard, Molines, Catherine, Retornaz, Frédérique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769181/
https://www.ncbi.nlm.nih.gov/pubmed/26918947
http://dx.doi.org/10.1371/journal.pone.0149732
_version_ 1782418066292867072
author Farcet, Anaïs
de Decker, Laure
Pauly, Vanessa
Rousseau, Frédérique
Bergman, Howard
Molines, Catherine
Retornaz, Frédérique
author_facet Farcet, Anaïs
de Decker, Laure
Pauly, Vanessa
Rousseau, Frédérique
Bergman, Howard
Molines, Catherine
Retornaz, Frédérique
author_sort Farcet, Anaïs
collection PubMed
description BACKGROUND: Comprehensive Geriatric Assessment (CGA) is the gold standard to help oncologists select the best cancer treatment for their older patients. Some authors have suggested that the concept of frailty could be a more useful approach in this population. We investigated whether frailty markers are associated with treatment recommendations in an oncogeriatric clinic. METHODS: This prospective study included 70 years and older patients with solid tumors and referred for an oncogeriatric assessment. The CGA included nine domains: autonomy, comorbidities, medication, cognition, nutrition, mood, neurosensory deficits, falls, and social status. Five frailty markers were assessed (nutrition, physical activity, energy, mobility, and strength). Patients were categorized as Frail (three or more frailty markers), pre-frail (one or two frailty markers), or not-frail (no frailty marker). Treatment recommendations were classified into two categories: standard treatment with and without any changes and supportive/palliative care. Multiple logistic regression models were used to analyze factors associated with treatment recommendations. RESULTS: 217 patients, mean age 83 years (± Standard deviation (SD) 5.3), were included. In the univariate analysis, number of frailty markers, grip strength, physical activity, mobility, nutrition, energy, autonomy, depression, Eastern Cooperative Oncology Group Scale of Performance Status (ECOG-PS), and falls were significantly associated with final treatment recommendations. In the multivariate analysis, the number of frailty markers and basic Activities of Daily Living (ADL) were significantly associated with final treatment recommendations (p<0.001 and p = 0.010, respectively). CONCLUSION: Frailty markers are associated with final treatment recommendations in older cancer patients. Longitudinal studies are warranted to better determine their use in a geriatric oncology setting.
format Online
Article
Text
id pubmed-4769181
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-47691812016-03-09 Frailty Markers and Treatment Decisions in Patients Seen in Oncogeriatric Clinics: Results from the ASRO Pilot Study Farcet, Anaïs de Decker, Laure Pauly, Vanessa Rousseau, Frédérique Bergman, Howard Molines, Catherine Retornaz, Frédérique PLoS One Research Article BACKGROUND: Comprehensive Geriatric Assessment (CGA) is the gold standard to help oncologists select the best cancer treatment for their older patients. Some authors have suggested that the concept of frailty could be a more useful approach in this population. We investigated whether frailty markers are associated with treatment recommendations in an oncogeriatric clinic. METHODS: This prospective study included 70 years and older patients with solid tumors and referred for an oncogeriatric assessment. The CGA included nine domains: autonomy, comorbidities, medication, cognition, nutrition, mood, neurosensory deficits, falls, and social status. Five frailty markers were assessed (nutrition, physical activity, energy, mobility, and strength). Patients were categorized as Frail (three or more frailty markers), pre-frail (one or two frailty markers), or not-frail (no frailty marker). Treatment recommendations were classified into two categories: standard treatment with and without any changes and supportive/palliative care. Multiple logistic regression models were used to analyze factors associated with treatment recommendations. RESULTS: 217 patients, mean age 83 years (± Standard deviation (SD) 5.3), were included. In the univariate analysis, number of frailty markers, grip strength, physical activity, mobility, nutrition, energy, autonomy, depression, Eastern Cooperative Oncology Group Scale of Performance Status (ECOG-PS), and falls were significantly associated with final treatment recommendations. In the multivariate analysis, the number of frailty markers and basic Activities of Daily Living (ADL) were significantly associated with final treatment recommendations (p<0.001 and p = 0.010, respectively). CONCLUSION: Frailty markers are associated with final treatment recommendations in older cancer patients. Longitudinal studies are warranted to better determine their use in a geriatric oncology setting. Public Library of Science 2016-02-26 /pmc/articles/PMC4769181/ /pubmed/26918947 http://dx.doi.org/10.1371/journal.pone.0149732 Text en © 2016 Farcet et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Farcet, Anaïs
de Decker, Laure
Pauly, Vanessa
Rousseau, Frédérique
Bergman, Howard
Molines, Catherine
Retornaz, Frédérique
Frailty Markers and Treatment Decisions in Patients Seen in Oncogeriatric Clinics: Results from the ASRO Pilot Study
title Frailty Markers and Treatment Decisions in Patients Seen in Oncogeriatric Clinics: Results from the ASRO Pilot Study
title_full Frailty Markers and Treatment Decisions in Patients Seen in Oncogeriatric Clinics: Results from the ASRO Pilot Study
title_fullStr Frailty Markers and Treatment Decisions in Patients Seen in Oncogeriatric Clinics: Results from the ASRO Pilot Study
title_full_unstemmed Frailty Markers and Treatment Decisions in Patients Seen in Oncogeriatric Clinics: Results from the ASRO Pilot Study
title_short Frailty Markers and Treatment Decisions in Patients Seen in Oncogeriatric Clinics: Results from the ASRO Pilot Study
title_sort frailty markers and treatment decisions in patients seen in oncogeriatric clinics: results from the asro pilot study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769181/
https://www.ncbi.nlm.nih.gov/pubmed/26918947
http://dx.doi.org/10.1371/journal.pone.0149732
work_keys_str_mv AT farcetanais frailtymarkersandtreatmentdecisionsinpatientsseeninoncogeriatricclinicsresultsfromtheasropilotstudy
AT dedeckerlaure frailtymarkersandtreatmentdecisionsinpatientsseeninoncogeriatricclinicsresultsfromtheasropilotstudy
AT paulyvanessa frailtymarkersandtreatmentdecisionsinpatientsseeninoncogeriatricclinicsresultsfromtheasropilotstudy
AT rousseaufrederique frailtymarkersandtreatmentdecisionsinpatientsseeninoncogeriatricclinicsresultsfromtheasropilotstudy
AT bergmanhoward frailtymarkersandtreatmentdecisionsinpatientsseeninoncogeriatricclinicsresultsfromtheasropilotstudy
AT molinescatherine frailtymarkersandtreatmentdecisionsinpatientsseeninoncogeriatricclinicsresultsfromtheasropilotstudy
AT retornazfrederique frailtymarkersandtreatmentdecisionsinpatientsseeninoncogeriatricclinicsresultsfromtheasropilotstudy